Research Article

Differential Expression of Matrix Metalloproteases in Human Fibroblasts with Different Origins

Diana Lindner, Christin Zietsch, P. Moritz Becher, Karsten Schulze, Heinz-Peter Schultheiss, Carsten Tschöpe, and Dirk Westermann

Department of Cardiology and Pneumology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany

Correspondence should be addressed to Diana Lindner, diana.lindner@charite.de

Received 1 September 2011; Accepted 25 November 2011

1. Introduction

Fibroblasts are a heterogeneous population of cells found in numerous tissues and are of mesenchymal origin. The most common products secreted by fibroblasts are components of the extracellular matrix (ECM) such as different types of collagen, fibronectin, and proteoglycans [1–5]. The ECM preserves the geometry and structural integrity of various organs and tissues, but it is not only a scaffold that provides support for cells, but is further involved in cell-cell interactions, proliferation, and migration. The dermis is composed of the predominating ECM and the fewer cellular constituents of mainly fibroblasts which provides flexibility and physical strength to skin [6]. In the heart fibroblasts are 70% of the cells in the myocardium, whereas myocytes occupy two-thirds of the tissue volume [7–9]. Pulmonary fibroblasts are also present in the connective tissue of the airway wall under the surface epithelium [10].

Moreover, fibroblasts are not only involved in the deposition of ECM products but also secrete ECM-degrading enzymes called matrix metalloproteases (MMPs) and therefore are involved in the degradation of ECM. These MMPs are zinc-dependent endopeptidases secreted by fibroblasts and functioning extracellularly [2, 4, 5, 11]. Their substrates are macromolecules of the ECM network consisting of different collagen types, proteoglycans, and glycoproteins. They are classified as collagenases, gelatinases, stromelysins, and membrane-type MMPs according to their substrate specificity. Collagenases cleave collagens at unique sites generating 75–25 kDa fragments called gelatins which were further degraded into single amino acids or oligopeptides by the gelatinases [12].

In this study we isolated three types of human fibroblasts, namely, cardiac, dermal, and pulmonary fibroblasts. We investigated the proliferation of fibroblasts in accordance to their different tissue origins to determine whether tissue-specific proliferation rates of this cell type can be found.

Furthermore, fibroblasts play a key role in normal matrix turnover as well as in pathological matrix deposition or degradation which can occur, for instance, during fibrosis...
or inflammation. We hypothesized tissue-specific expression levels of MMPs in the different types of fibroblasts. Therefore, we determined the basal MMP expression of primary human fibroblasts derived from heart, lung, and skin. Thereby we focused on these MMPs which are described to be expressed in cardiac tissue [2].

TNF-α is a proinflammatory cytokine, which plays a key role in myocardial inflammatory response after myocardial infarction [13]. In the early stage, the predominant sources of TNF-α are the infiltrated inflammatory cells. In this study we demonstrate different MMP expression of fibroblasts according to their site of origin in response to TNF-α.

2. Materials and Methods

2.1. Isolation and Culture of Human Cardiac, Dermal, and Pulmonary Fibroblasts. Human cardiac, dermal, and pulmonary fibroblasts were obtained by outgrowth from biopsies from four, three, or two patients, respectively. The endomyocardial fibroblasts were obtained by outgrowth from biopsies of patients with dilated cardiomyopathy. Human cardiac, dermal, and pulmonary fibroblasts (Pulmonary Fibroblasts).

2.2. Immunofluorescence Staining of Primary Human Fibroblasts. Cells to be characterized were seeded out into 48-well plates and grown to approximately 80% confluence. Cells were then fixed in 4% paraformaldehyde at room temperature for 10 minutes. Subsequently, cells were permeabilized with 0.25% Triton X-100 in TBS for 10 minutes followed by blocking with TBS containing 0.25% Triton X-100 and 1.5% normal rabbit serum for vimentin and desmin staining or 1.5% normal horse serum for CD31 staining or 1.5% normal rabbit serum for vimentin and desmin staining. For fluorescence visualization cells were finally incubated with 9 μg/mL Cy3-conjugated streptavidin (016-160-084, Jackson ImmunoResearch, Suffolk, UK) diluted in TBS containing 0.25% Triton X-100 for 30 minutes followed by a nuclear staining with Dapi (D1168, Invitrogen, Darmstadt, Germany) for 10 minutes. Cells were covered with TBS and analysed by fluorescence microscopy.

2.3. Proliferation of Primary Human Fibroblasts. To determine the doubling time of fibroblasts they were seeded out into 96-well plates and allowed to attach for 48 hours. Every second or third day only three wells of the 96-well plates were incubated with CellTiter-Blue viability solution (Promega, Mannheim, Germany) diluted in complete cell culture medium as recommended and incubated at 37°C in a humidified atmosphere with 5% CO₂ and 95% air for 2 hours. The colour development was monitored at 560 nm with a reference wave length of 620 nm. Growth curves were plotted as x-fold of reference corrected optical density (OD) compared to the first measurement 48 hours after seeding. The doubling time was calculated using following formula, DT = [t − t₀] log 2 / [log N − log N₀], where N₀ and Nₜ are the detected OD₅₆₀–₆₂₀ at times t and t₀, respectively.

2.4. Stimulation of Human Fibroblasts. For stimulation experiments the primary human fibroblasts were seeded out into 24-well plates. When the culture was about 80% confluence, cells were washed once and serum-starved in Iscove’s basal medium (Biochrom AG, Berlin, Germany) containing 10% human serum, 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (PAA, Colbe, Germany) at 37°C in a humidified atmosphere with 5% CO₂ and 95% air. All further experiments were done with cells between the second and the fourth passage.

2.5. RNA Isolation, cDNA Transcription, and Real-Time PCR. Total RNA was isolated from cells using RNAeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Briefly, after cell lysis with RLT-Buffer containing 1% mercaptoethanol and stored at −80°C until total RNA isolation. Stimulation experiments were carried out with n = 6 wells per experiment for all patients and repeated at least twice for each patient.

minutes. For fluorescence visualization cells were finally incubated with 9 μg/mL Cy3-conjugated streptavidin (016-160-084, Jackson ImmunoResearch, Suffolk, UK) diluted in TBS containing 0.25% Triton X-100 for 30 minutes followed by a nuclear staining with Dapi (D1168, Invitrogen, Darmstadt, Germany) for 10 minutes. Cells were covered with TBS and analysed by fluorescence microscopy.
Figure 1: Characterization of primary human fibroblasts. Cells were obtained by outgrowth form tissue samples from heart, skin, and lung. They were stained with antibody directed against vimentin, desmin, CD31, and P4HB. They show positive staining for vimentin and P4HB and were therefore characterized as fibroblasts.

Water. The yield of purified total RNA was determined by measuring the UV absorbance at 260 nm on the Nanodrop ND1000 spectrophotometer. cDNA was obtained from 250 ng total RNA using the high-capacity kit (Applied Biosystems) according to the manufacturer's protocol and finally diluted to a concentration of 1.25 ng/μL for further analysis. To assess the mRNA expression of the target genes real-time PCR was performed using 5 μL of the gene expression master mix (Applied Biosystems) and the 0.5 μL of the gene expression assay for Col1A1 (Hs00164004_m1), MMP1 (Hs00233958_m1), MMP2 (Hs00234422_m1), MMP3 (Hs00968305_m1), MMP7 (Hs01042795_m1), MMP8 (Hs00233972_m1), MMP9 (Hs00234579_m1), MMP13 (Hs00122992_m1), and MMP14 (Hs00237119_m1) (each includes forward and reverse primers as well the fluorescently FAM-labelled probe) from Applied Biosystems and 1 μL LcDNA in a final volume of 10 μL. Quantification of the house-keeping gene CDKN1b (Hs00153277_m1) as an internal control was performed for each sample. All data were normalized to CDKN1b mRNA level as an endogenous control (unaffected by TNF-α treatment). In figures as well as in Table 1 the data are expressed as absolute mRNA expression levels using the formula $2^{-\Delta\Delta Ct}$. To highlight the different response to external stimuli the data in Table 2 are expressed as relative mRNA expression levels using the formula $2^{-\Delta Ct}$.

2.7. Statistical Analysis. Data are shown as mean ± SEM. For comparison the nonparametric Mann-Whitney U test was used. Differences were considered significant when the probability value $P$ is lower than 0.05. All analyses were performed using Graph Pad Prism 5.0 software (GraphPad Software, La Jolla, CA).

3. Results

3.1. Characterization of Human Fibroblasts. To positively identify the cells populating our primary cultures as fibroblasts, the cells obtained by the outgrowth from biopsies were stained with different markers (Figure 1). Cardiac, dermal, and pulmonary presumable fibroblasts as well as the cardiomyocyte cell line HL1 and the endothelial cell line HMEC-1 expressed the cytosolic localized structural protein vimentin. Furthermore, the primary cells did not express the muscle marker desmin and the endothelial cell surface marker CD31 in contrast to the HL1 and the HMEC-1.
compared to the expression in cardiac fibroblasts using Mann-Whitney U test. For statistical significance dermal or pulmonary expression was compared to the expression in cardiac fibroblasts using Mann-Whitney U test.

### Table 1: Absolute mRNA expression levels of different MMPs in cardiac, dermal, and pulmonary human fibroblasts. The mRNA expression was normalized to the housekeeping gene CDKN1b using the formula $2^{-\Delta\Delta C_t}$. For statistical significance dermal or pulmonary expression was compared to the expression in cardiac fibroblasts using Mann-Whitney U test.

| Gene     | Cardiac fibroblast | Dermal fibroblast | Pulmonary fibroblast | P value | P value |
|----------|--------------------|-------------------|----------------------|---------|---------|
|          | Expression         | x-fold to cardiac fibroblast |          | Expression         | x-fold to cardiac fibroblast |          |
| MMP1     | 12 ± 3             | 0.49 ± 0.08       | 24                   | <0.0001 | 0.67 ± 0.12       | 17         | <0.0001 |
| MMP2     | 104 ± 10           | 111 ± 6           | 1.1                  | 0.559   | 88 ± 8            | -1.2       | 0.411   |
| MMP3     | 0.29 ± 0.08        | 2.1 ± 0.3         | 7.0                  | <0.0001 | 0.033 ± 0.007     | -8.9       | 0.155   |
| MMP7     | 0.005 ± 0.001      | 0.0024 ± 0.0006   | -2.0                 | 0.013   | 0.0005 ± 0.0001  | -9.2       | <0.0001 |
| MMP8     | 0.040 ± 0.013      | 0.0006 ± 0.0002   | -63                  | <0.0001 | 0.0007 ± 0.0002  | -54        | <0.0001 |
| MMP9     | 0.010 ± 0.003      | 0.028 ± 0.005     | 2.7                  | 0.003   | 0.0055 ± 0.0012  | -1.9       | 0.292   |
| MMP14    | 41 ± 5             | 15 ± 1            | -2.8                 | <0.0001 | 26 ± 2           | -1.6       | 0.033   |

3.2. Proliferation. To determine the different growth rate of primary human fibroblasts with different origins, cardiac, dermal, and pulmonary fibroblasts were seeded out into 96-well plates and cultured in complete growth medium for 14 days. After different time periods cells were incubated with cellTiter viability assay and the colour development was monitored. The first measurement was done 48 hours after seeding out. Growth curves of cardiac, dermal, and pulmonary fibroblasts in complete growth medium are presented in Figure 2(a). It is clearly shown that cardiac fibroblasts proliferate much slower compared to fibroblasts derived from skin or lung. The calculated doubling time of cardiac fibroblasts was with 12.2 days approximately 4-fold longer compared to the doubling time of 3.7 and 3.3 days of the dermal and pulmonary fibroblasts, respectively.

3.3. Basal Expression of Collagen and Matrix Metalloproteases in Cardiac, Dermal, and Pulmonary Fibroblasts. To investigate the basal expression levels of fibroblasts according to their site of origin the mRNA expression level of the untreated control cells after incubation in serum-starved medium for approximately 16 and additional 24 hours was determined using real-time PCR analysis. Therefore, total RNA was extracted from cells and transcribed into cDNA followed by TaqMan for quantification. The determined mRNA expression levels for Col1A1 and MMPs are shown in Figures 2(b) and 2(c), respectively.

A similar collagen 1A1 expression level was found in cardiac and pulmonary fibroblasts. Interestingly an approximately 2-fold higher expression of collagen 1A1 was determined in dermal fibroblasts.

The most abundant MMP in all three types of fibroblasts is MMP2 followed by MMP14. As shown in Table 1

| Gene     | Cardiac fibroblast | Dermal fibroblast | Pulmonary fibroblast | P value | P value |
|----------|--------------------|-------------------|----------------------|---------|---------|
|          | expression         | x-fold to cardiac fibroblast |          | expression         | x-fold to cardiac fibroblast |          |
| MMP1     | 2.0 ± 0.2          | 0.044             | 100 ± 12             | <0.0001 | 6.0 ± 0.8        | <0.0001 |
| MMP2     | 1.6 ± 0.1          | 0.0002            | 1.2 ± 0.1            | 0.023   | 1.2 ± 0.0        | 0.007    |
| MMP3     | 6.7 ± 1.2          | <0.0001           | 9.8 ± 1.8            | <0.0001 | 16 ± 3           | <0.0001 |
| MMP7     | 16 ± 4             | <0.0001           | 3.3 ± 0.3            | <0.0001 | 3.1 ± 0.5        | 0.006    |
| MMP8     | 5.7 ± 1.2          | <0.0001           | 130 ± 50             | <0.0001 | 10 ± 2           | <0.0001 |
| MMP9     | 7.5 ± 2.4          | 0.005             | 127 ± 27             | <0.0001 | 90 ± 11          | <0.0001 |
| MMP14    | 1.6 ± 0.1          | 0.018             | 1.6 ± 0.3            | 0.103   | 1.2 ± 0.1        | 0.317    |
Figure 2: Proliferation, collagen expression, and basal MMP expression of cardiac, dermal, and pulmonary fibroblasts. (a) Growth curves were determined in complete growth medium for fibroblasts derived from heart, skin, and lung. Cardiac fibroblasts reveal a lower proliferation rate compared to dermal and pulmonary fibroblasts. (b) Collagen mRNA expression level was determined using TaqMan from fibroblasts incubated with or without 10 ng/mL TNF-α for 24 hours. Untreated dermal fibroblasts show a significantly higher expression level of collagen (§§§) compared to untreated cardiac and pulmonary fibroblasts, whereas only in dermal and pulmonary fibroblasts TNF-α treatment resulted in significantly decreased collagen expression compared to untreated controls (***). (c) Basal expression levels of different MMPs in dermal and pulmonary fibroblasts were compared to their expression in cardiac fibroblasts. The most obvious difference is shown for MMP1 and MMP3. All mRNA expression levels are shown as absolute expression using the formula $2^{-\Delta\Delta Ct}$.

The absolute mRNA expression level of MMP2 does not differ significantly between cardiac, dermal, and pulmonary fibroblasts, whereas the membrane-bound MMP14 (MT1-MMP) is significantly 2.8-fold lower expressed in dermal fibroblasts compared to cardiac fibroblasts.

In all three fibroblast types MMP1 is the most expressed interstitial collagenase whereas the expression in cardiac fibroblasts is significantly 24-fold and 17-fold higher as in dermal or in pulmonary fibroblasts, respectively. The rarely expressed collagenase MMP8 is significantly 63-fold and
54-fold higher expressed in cardiac fibroblasts as well compared to fibroblasts derived from skin or lung, respectively. The collagenase MMP13 could not be detected in all three types of fibroblasts (data not shown).

We further investigated the stromelysins MMP3 and MMP7. Both MMPs are quite low expressed in cardiac fibroblasts, whereas MMP3 is more expressed than MMP7 in all three fibroblast types. When compared to the expression level in cardiac fibroblasts MMP3 is significantly 7.0-fold higher expressed in dermal fibroblasts, whereas it is 8.9-fold lower expressed in pulmonary fibroblasts but in this case it did not reach a significant level (P value > 0.05). The stromelysin MMP7 is significantly 2.0-fold and 9.2-fold lower expressed in dermal and pulmonary fibroblasts regarding cardiac fibroblasts, respectively.

The gelatinase MMP9 is one of the lower expressed MMPs in fibroblasts. In dermal fibroblasts the mRNA expression level is 2.7-fold higher and in pulmonary fibroblasts 1.9-fold lower concerning the mRNA expression in cardiac fibroblasts.

3.4. Expression of Collagen and Matrix Metalloproteases in Cardiac, Dermal, and Pulmonary Fibroblasts after TNF-α Treatment. To explore the influence of TNF-α treatment on the expression of collagen we incubated fibroblasts with 10 ng/mL TNF-α for 24 hours. After extracting the total RNA and transcribing that into cDNA TaqMan analysis was performed. In Figure 2(b) the impact of TNF-α on collagen expression is presented. Whereas TNF-α treatment resulted in a 2-fold decreased expression of collagen in fibroblasts derived from skin or lung, there was no influence detectable in cardiac fibroblasts.

Concerning the mRNA expression of MMPs TNF-α treatment induced an increased expression of all investigated MMPs in general, whereas the impact of TNF-α on the expression of the gelatinase MMP2 and membrane-bound MMP14 (MT1-MMP) did not even reach 2.0-fold increase (Table 2).

In more detail, MMP1 expression was increased 2.0-fold, 100-fold, and 6.0-fold in cardiac, dermal, and pulmonary fibroblasts, respectively (Table 2). In Figure 3(a) it is clearly shown that the TNF-α treatment finally leads to a similar mRNA expression of MMP1 in cardiac and dermal fibroblasts, whereas MMP1 is still significantly lower expressed after TNF-α treatment in pulmonary fibroblasts compared to the cardiac expression levels. Concerning the TNF-α-induced change in expression levels of the collagenase MMP8 similar results could be observed. TNF-α leads to an increase of 5.7-fold and 130-fold in cardiac and dermal fibroblasts, respectively, resulting finally in comparable expression levels of MMP8 in cardiac and dermal fibroblasts which demonstrate that no significant difference could be observed after TNF-α treatment in contrast to the properties prior to stimulation. In pulmonary fibroblasts the expression of MMP8 was increased by a factor of 10, but still significantly lower than in cardiac fibroblasts.

In cardiac fibroblasts the stromelysin MMP3 expression was 6.7-fold increased by TNF-α, whereas in dermal and pulmonary fibroblasts an extended increase of mRNA expression with 9.8-fold and 16-fold was observed, respectively. However, the resulted MMP3 expression did not differ between fibroblasts derived from heart or lung (Figure 3(b)). In contrast TNF-α leads with 3.3-fold and 3.1-fold to a slight increase of MMP7 mRNA expression in dermal and pulmonary fibroblasts, respectively. However, in cardiac fibroblasts MMP7 is 16-fold higher expression after TNF-α treatment.

Interestingly, a high impact of TNF-α on MMP9 expression was observed in dermal and pulmonary fibroblasts (127-fold and 90-fold) whereas in cardiac fibroblasts the resulted change of mRNA expression level was relatively low with an increase of 7.5-fold. Furthermore, to examine the MMP9 secretion zymography was used to determine the protein content of MMP9 in the cell culture supernatants of cardiac, dermal and pulmonary fibroblasts. In the cell culture supernatant of cardiac fibroblasts no MMP9 was detected. In contrast, dermal, and pulmonary fibroblasts secreted low amounts of MMP9 which were significantly increased by TNF-α treatment (Figure 3(c)).

4. Discussion

In this study we investigated human primary fibroblasts derived from different types of tissue. We examined the proliferation rate, the expression of collagen, and the collagen degrading MMPs of quiescent fibroblasts and compared this basal expression pattern between the different types of fibroblasts. Furthermore, we determined the changes of mRNA expression in these investigated types of fibroblasts after stimulation with the proinflammatory cytokine TNF-α to determine differences between fibroblasts isolated from heart, skin, and lung tissues. Interestingly, these three types of fibroblasts reveal major differences in proliferation rate and MMP expression.

Regarding other studies focused on fibroblasts expression we suggested that heterogeneities can be identified [14–17]. It has been reported that even within the single tissue skin fibroblasts occur with different properties concerning the site of origin since dermal fibroblasts from different anatomical sites show similar morphology but their own gene expression profile [17]. Here we focused on the expression pattern of the ECM degradation system which includes the MMPs and compared this between fibroblasts derived from different organs.

First, we characterized these outgrowth cells using fluorescence microscopy. The cultured cells from heart, skin, and lung tissue showed similar morphology. They appear as elongated spindle-shaped cells and revealed positive staining for vimentin and P4HB. To exclude contaminations with other cells than the expected fibroblasts, for instance, endothelial cells or muscle cells such as cardiomyocytes from the heart [18], we stained the cultured cells further with the muscle marker desmin and the endothelial marker CD31. Since nearly no positive cells were obtained by this staining
we conclude that the presumable fibroblast cultures from heart, skin, and lung contain almost exclusively primary fibroblasts.

The fibroblast cell type itself is already known as a proliferating cell [3, 19, 20]. Moreover, we compared the growth rate of these fibroblasts according to their site of origin. We clearly demonstrated that fibroblasts derived from skin or lung revealed a much higher proliferation rate compared to cardiac fibroblasts. According to the function of the organ from which the fibroblasts are derived the found differences
are explainable. Skin is the largest organ of the body and plays crucial role in protecting against external injuries. Skin wound can arise from environmental influences such as mechanical exposures, surgical procedures, or burns. Most skin wounds can heal naturally due to the existence of highly proliferating cells which could be a satisfying explanation for the determined high growth rate of dermal fibroblasts. An equal proliferation was observed for pulmonary fibroblasts. Again environmental influences are able to reach lung tissue easily by the airway. Therefore, the ability to renew lung tissue is essential as well [10].

In contrast to skin and lung, for cardiac fibroblasts a 4-fold higher doubling time was determined. The heart is not directly open for environmental influences but is situated within the body and only exposed to the closed system the blood circulation. Therefore, outside influences such as bacteria or virus cannot easily reach the heart without passing blood vessels. However, further injuries such as myocardial infarction can occur without direct contact to the environment. But the probability for such injuries of the heart is much lower than for injuries of skin or lung surface. Even if the fibroblast is the most numerous cell type in the heart, cardiomyocytes occupy two-thirds of the tissue volume [7–9]. In contrast to fibroblasts these cells are not able to proliferate after birth [21]. Consequently after myocardial infarction cardiomyocyte death occurs, followed by migration and proliferation of fibroblasts and changes in synthesis and degradation of ECM [3].

Since fibroblasts are the common producers of ECM consisting mainly of collagen, we determined the mRNA expression level of the quiescent dermal, pulmonary, and cardiac fibroblasts. Cardiac and pulmonary fibroblasts exhibit an equal expression level of collagen type I in contrast to dermal fibroblasts revealing a 2-fold higher expression. We further investigated the collagen expression of the fibroblast types after TNF-α treatment. TNF-α is one of the most prominent proinflammatory cytokines which is highly released in response to a large number of inflammatory stimuli, such as LPS or virus antigens [22]. In kidney mesangial cell cultures treated with TNF-α, alone a mild but inconsistent reduction in baseline collagen type I level has been detected [23]. Furthermore, TNF-α was a consistent and potent inhibitor of the collagen augmentation stimulated by the profibrotic growth factor TGF-β. It has been reported that TNF-α exerted a suppressive effect on Smad3/4 DNA-binding activity [24] being a potential explanation for the often described antifibrotic effect of TNF-α [23–29]. In agreement with these data we found significantly reduced collagen mRNA levels after TNF-α treatment in fibroblasts derived from skin and lung but no influence of TNF-α on the collagen expression was observed in cardiac fibroblasts.

Next, we focused on the expression of the proteolytic ECM degradation system in quiescent dermal, pulmonary, and cardiac fibroblasts. The MMPs can exist as either soluble or membrane-type MMPs. Soluble MMPs are synthesized in a latent form called pro-MMP. These inactive proenzyme are secreted into the extracellular space where they bind to specific ECM protein and remain quiescent until the prodomain is cleaved off [5]. It is known that this cleaving can be performed by other MMPs [4]. Conversely, the MT-MMPs incorporate a transmembrane region and are inserted into the cell membranes in a fully active state. The family of these enzymes includes a number of members with various and partly overlapping specificities [2, 5]. Therefore, the MMP family is divided into three groups: collagenases (MMP1, MMP8, and MMP13) which predominantly degrade interstitial collagen type I, II, and III, gelatinases (MMP2 and MMP9) degrading gelatin and basement membrane collagen such as collagen IV as well as stromelysins (MMP3 and MMP7) which digest a broad range of substrates such as collagen IV, proteoglycans, laminin, gelatins, and fibronectin [2, 4, 5].

MMP1 is the most expressed soluble collagenase in all three types of fibroblasts, whereas its expression was about 20-fold higher in cardiac fibroblasts compared to dermal and pulmonary fibroblasts. MMP8 is very low expressed but also most expressed in the cardiac fibroblasts. MMP13 could not be detected in all three human types of fibroblasts, whereas this collagenase has been referred to as rodent collagenase, since this is the primary collagenase found in rodents [4].

Another obvious difference in the basal expression pattern of MMPs was found for the stromelysin MMP3 which is most expressed in dermal fibroblasts. It has been reported from fetal skin in comparison to fetal lung fibroblasts that the net-like collagen type IV is relatively high expressed in skin [17]. Since MMP3 is able to digest collagen type IV its higher abundance in skin could be expected.

MMPs catalyze the degradation of ECM macromolecules such as the interstitial and basement membrane collagens and therefore facilitate cell migration of inflammatory cells into the injured tissue. The invading inflammatory cells secrete the proinflammatory cytokine TNF-α. Thus we further examined the consequences for MMP expression of fibroblasts after TNF-α treatment. It has recently been shown that the proinflammatory cytokine TNF-α is one transcriptional activator for MMP9 in dermal human fibroblasts [30].

Collagen type I is the most expressed collagen in the heart. Further collagen I and V are strongly expressed in fetal skin but not in fetal lung fibroblasts [17]. It has already been reported that TNF-α induced MMP1 mRNA and protein expression in dermal, gingival, and synovial fibroblasts [31]. In our experiments the TNF-α treatment also revealed an extreme increase of the collagenase MMP1 in fibroblasts derived from skin which then reach the equal expression level as determined in cardiac fibroblasts. In almost the same manner in dermal fibroblasts MMP8 was as well increased to a similar level compared to cardiac fibroblasts after TNF-α treatment. Finally both soluble collagenases are significantly lower expressed in quiescent dermal and pulmonary fibroblasts but TNF-α treatment leads to an equal level of MMP1 and MMP8 as described for cardiac fibroblast in dermal but not in pulmonary fibroblasts.

The expression of the stromelysins MMP3 and MMP7 is as well differentially regulated by TNF-α. Whereas MMP3 is most expressed in dermal fibroblasts the expression between cardiac and pulmonary fibroblasts did not differ significantly with or without TNF-α treatment. In contrast MMP7 is
most expressed and highly up-regulated by TNF-α in cardiac fibroblasts compared to fibroblasts from skin or lung.

Furthermore, an extreme upregulation of the gelatinase MMP9 was determined in dermal and pulmonary fibroblasts compared to a weak upregulation in cardiac fibroblasts. This difference leads to detectable secreted MMP9 protein using zymography in dermal and pulmonary fibroblasts but not in cardiac fibroblasts. One substrate of MMP9 is collagen IV, the net-like collagen which forms the basement membrane, and therefore MMP9 facilitates cell migration into the injured tissue.

As already mentioned, the activity of MMPs is regulated through transcriptional activators such as TNF-α. Furthermore, the presence of active MMPs is also regulated by control of posttranslational cleaving and the presence of endogenous inhibitors so-called tissue inhibitor of MMPs (TIMPs). These TIMPs bind noncovalently to the catalytic domain of MMPs in a 1:1 stoichiometry and therefore prevent the access of the substrate to the active site of the enzyme [32]. Proteolysis becomes pathological, when the normal balance between MMPs and their inhibitors TIMPs is lost. In this study we focused on the transcriptional regulation but several studies have been performed to get a better understanding for the posttranslational control. For instance in the presence of MMP3 a 12-fold increase, in the conversion of proMMP1 to active MMP1 was reported [33]. In other studies, inflammatory cytokines such as IL-1α are known to play a major role in regulating MMP and TIMP expression in several inflammatory diseases. The stimulatory effect of IL-1α as well as TNF-α has been reported for both the expression of MMPs and TIMPs in dental pulp fibroblasts which leads to an alteration of the balance between the MMPs and TIMPs [34, 35].

Beyond their effects on matrix degradation to facilitate the invasion of inflammatory cells, MMPs can further modulate inflammatory pathways by processing cytokines, chemokines, and growth factors. For example, MMP7 and the membrane-bound MMP14 have both been identified to serve as unifying cell population with comparable function regardless of their origin. Here we demonstrated serious differences in proliferation, collagen synthesis as well as MMP expression under basal or inflammatory conditions. However, an excess of MMPs resulting in degradation of ECM is thought to be a key feature of the pathology of various inflammatory and degenerative diseases [41–43]. Since extensive heterogeneity among fibroblasts from different tissues has been demonstrated, it is essential to examine cardiac fibroblasts to understand myocardial dysfunctions even if it is more difficult to obtain and to cultivate cardiac fibroblasts.

Acknowledgments

The present study was supported by the Deutsche Forschungsgemeinschaft (DFG, SFB-TR-19, TP A2) and by the European Commission, Research Directorate General, FP7-Health-2010, Media (261409), Brussels. The authors thank Nadine Orrin, Kerstin Puhl, and Georg Zingler for technical assistance.

References

[1] R. D. Brown, S. K. Ambler, M. D. Mitchell, and C. S. Long, “The cardiac fibroblast: therapeutic target in myocardial remodeling and failure,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 657–687, 2005.
[2] H. K. Graham, M. Horn, and A. W. Trafford, “Extracellular matrix profiles in the progression to heart failure: European young physiologists symposium keynote lecture-bratislava 2007,” Acta Physiologica, vol. 194, no. 1, pp. 3–21, 2008.
[3] K. E. Porter and N. A. Turner, “Cardiac fibroblasts: at the heart of myocardial remodeling,” Pharmacology and Therapeutics, vol. 123, no. 2, pp. 255–278, 2009.
[4] F. G. Spinale, “Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function,” Physiological Reviews, vol. 87, no. 4, pp. 1285–1342, 2007.
[5] F. G. Spinale, M. L. Coker, B. R. Bond, and J. L. Zellner, “Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target,” Cardiovascular Research, vol. 46, no. 2, pp. 225–238, 2000.
[6] S. P. Zhong, Y. Z. Zhang, and C. T. Lim, “Tissue scaffolds for skin wound healing and dermal reconstruction,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 2, no. 5, pp. 510–525, 2010.
[7] I. Banerjee, J. W. Fuseler, R. L. Price, T. K. Borg, and T. A. Baudino, “Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse,” American Journal of Physiology, vol. 293, no. 3, pp. H1883–H1891, 2007.
[8] I. Banerjee, K. Yekkala, T. K. Borg, and T. A. Baudino, “Dynamic interactions between myocytes, fibroblasts, and extracellular matrix,” Annals of the New York Academy of Sciences, vol. 1080, pp. 76–84, 2006.
[9] E. C. Goldsmith, A. Hoffman, M. O. Morales et al., “Organization of fibroblasts in the heart,” Developmental Dynamics, vol. 230, no. 4, pp. 787–794, 2004.
[10] G. M. Roomans, “Tissue engineering and the use of stem/progenitor cells for airway epithelium repair,” European Cells & Materials, vol. 19, pp. 284–299, 2010.
[11] J. Kukacka, R. Průša, K. Kotaska, and V. Pelouch, “Matrix metalloproteinases and their function in myocardium,” Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, vol. 149, no. 2, pp. 225–236, 2005.
[12] F. J. Villarreal, M. Griffin, J. Omens, W. Dillmann, J. Nguyen, and J. Covell, “Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling,” Circulation, vol. 108, no. 12, pp. 1487–1492, 2003.
[13] N. A. Turner, R. S. Mughal, P. Warburton, D. J. O’Regan, S. G. Ball, and K. E. Porter, “Mechanism of TNFα-induced IL-1α,
IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones," Cardiovascular Research, vol. 76, no. 1, pp. 81–90, 2007.

[14] E. Breen, V. M. Falco, M. Absher, and K. R. Cutroneo, “Subpopulations of rat lung fibroblasts with different amounts of type I and type III collagen mRNAs,” Journal of Biological Chemistry, vol. 265, no. 11, pp. 6286–6290, 1990.

[15] H. Okada, S. Ban, S. Nagao, H. Takahashi, H. Suzuki, and E. G. Neilson, “Progressive renal disease in routine polycystic kidney disease: an immunohistochemical observation,” Kidney International, vol. 58, no. 2, pp. 387–397, 2000.

[16] A. Jelaska, D. Strehlow, and J. H. Korn, “Fibroblast heterogeneity in physiological conditions and fibrotic disease,” Springer Seminars in Immunopathology, vol. 21, no. 4, pp. 385–395, 1999.

[17] H. Y. Chang, J. T. Chi, S. Dudoit et al., “Diversity, topographic differentiation, and positional memory in human fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 12877–12882, 2002.

[18] T. Thum, C. Gross, J. Friedler et al., “MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts,” Nature, vol. 456, no. 7224, pp. 980–984, 2008.

[19] T. Yano, T. Miura, Y. Ikeda et al., “Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair,” Cardiovascular Pathology, vol. 14, no. 5, pp. 241–246, 2005.

[20] T. Wong, J. A. McGrath, and H. Navaesrini, “The role of fibroblasts in tissue engineering and regeneration,” British Journal of Dermatology, vol. 156, no. 6, pp. 1149–1155, 2007.

[21] M. J. van Amerongen and F. B. Engel, “Features of cardiomyocyte proliferation and its potential for cardiac regeneration: stem cells review series,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6A, pp. 2233–2244, 2008.

[22] S. von Haehling, E. A. Jankowska, and S. D. Anker, “Tumour necrosis factor-α and the failing heart: pathophysiology and therapeutic implications,” Basic Research in Cardiology, vol. 99, no. 1, pp. 18–28, 2004.

[23] L. A. Cooker, D. Peterson, J. Rambow et al., “TNF-α, but not IFN-γ, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis,” American Journal of Physiology, vol. 293, no. 1, pp. F157–F165, 2007.

[24] J. A. Roman-Blas, D. G. Stokes, and S. A. Jimenez, “Modulation of TGF-β signaling by proinflammatory cytokines in articular chondrocytes,” Osteoarthritis and Cartilage, vol. 15, no. 12, pp. 1367–1377, 2007.

[25] A. Mauviel, M. Daireaux, F. Redini, P. Galera, G. Loyau, and J. P. Pujol, “Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts,” FEBS Letters, vol. 236, no. 1, pp. 47–52, 1988.

[26] C. Ghizziolani, Y. Parel, C. De Luca et al., “Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α,” Arthritis and Rheumatism, vol. 46, no. 9, pp. 2593–2604, 2003.

[27] D. J. Koub, K. Y. Chung, T. Nishiyama et al., “Nuclear factor-κB mediates TNF-α inhibitory effect on α2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts,” Journal of Immunology, vol. 162, no. 7, pp. 4226–4234, 1999.

[28] F. Verrecchia, E. F. Wagner, and A. Mauviel, “Distinct involvement of the Jun-N-terminal kinase and NF-κB pathways in the repression of the human COL1A2 gene by TNF-α,” EMBO Reports, vol. 3, no. 11, pp. 1069–1074, 2002.

[29] F. Verrecchia, M. Pessah, A. Atfi, and A. Mauviel, “Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation,” Journal of Biological Chemistry, vol. 275, no. 39, pp. 30226–30231, 2000.

[30] L. Zhou, C. Yan, R. G. Giedling et al., “Tumor necrosis factor-α inhibitory effect of expression of matrix metalloproteinase-9 through p21-activated Kinase-1,” BMC Immunology, vol. 10, article 15, 2009.

[31] J.-M. Dayer, B. Beutler, and A. Cerami, “Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts,” Journal of Experimental Medicine, vol. 162, no. 6, pp. 2163–2168, 1985.

[32] T. E. Cawston, V. A. Curry, I. M. Clark, and B. L. Hazleman, “Identification of a new metalloproteinase inhibitor that forms tight-binding complexes with collagenase,” Biochemical Journal, vol. 269, no. 1, pp. 183–187, 1990.

[33] G. Murphy, M. I. Cockett, P. E. Stephens, B. J. Smith, and A. J. P. Docherty, “Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes,” Biochemical Journal, vol. 248, no. 1, pp. 265–268, 1987.

[34] K. Wisithphrom and L. J. Windsor, “The effects of tumor necrosis factor-α, interleukin-1β, interleukin-6, and transforming growth factor-β1 on pulp fibroblast mediated collagen degradation,” Journal of Endodontics, vol. 32, no. 9, pp. 853–861, 2006.

[35] K. Wisithphrom, P. E. Murray, and L. J. Windsor, “Interleukin-1α alters the expression of matrix metalloproteinases and collagen degradation by pulp fibroblasts,” Journal of Endodontics, vol. 32, no. 3, pp. 186–192, 2006.

[36] A. J. H. Gearing, P. Beckett, M. Christodoulou et al., “Matrix metalloproteinases and processing of pro-TNF-α,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 774–777, 1995.

[37] S. E. Gill and W. C. Parks, “Metalloproteinases and their inhibitors: regulators of wound healing,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 6-7, pp. 1334–1347, 2008.

[38] M. Dobaczewski, C. Gonzalez-Queresa, and N. G. Frangogiannis, “The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 48, no. 3, pp. 504–511, 2010.

[39] G. A. McQuibban, J. H. Gong, E. M. Tam, C. A. G. McCulloch, I. Clark-Lewis, and C. M. Overall, “Inflammation dampened by gelatinase a cleavage of monocyte chemotactrant protein-3,” Science, vol. 289, no. 5482, pp. 1202–1206, 2000.

[40] D. Westermann, K. Savvatis, D. Lindner et al., “Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy,” Circulation, vol. 124, no. 19, pp. 2082–2093, 2011.

[41] P. Brenneisen, H. Sies, and K. Scharoff-Kochanek, “Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events,” Annals of the New York Academy of Sciences, vol. 973, pp. 31–43, 2002.

[42] V. M. Kähäri and U. Saarialho-Kere, “Matrix metalloproteinases in skin,” Experimental Dermatology, vol. 6, no. 5, pp. 199–213, 1997.

[43] A. Luikes, S. Mun-Bryce, M. Luikes, and G. A. Rosenberg, “Extracellular matrix degradation by metalloproteinases and central nervous system diseases,” Molecular Neurobiology, vol. 19, no. 3, pp. 267–284, 1999.